153 related articles for article (PubMed ID: 31663456)
21. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
22. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
23. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
24. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
Su F; Beste LA; Green PK; Berry K; Ioannou GN
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
[TBL] [Abstract][Full Text] [Related]
25. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
[TBL] [Abstract][Full Text] [Related]
26. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
[TBL] [Abstract][Full Text] [Related]
27. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
28. Risk of
Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
[TBL] [Abstract][Full Text] [Related]
29. Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection.
Ottman AA; Townsend ML; Hashem MG; DiMondi VP; Britt RB
Ann Pharmacother; 2018 Aug; 52(8):763-768. PubMed ID: 29577765
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
Chhatwal J; Chen Q; Ayer T; Bethea ED; Kanwal F; Kowdley KV; Wang X; Roberts MS; Gordon SC
Aliment Pharmacol Ther; 2018 Apr; 47(7):1023-1031. PubMed ID: 29377245
[TBL] [Abstract][Full Text] [Related]
31. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
[TBL] [Abstract][Full Text] [Related]
32. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
[TBL] [Abstract][Full Text] [Related]
34. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
Cartwright EJ; Pierret C; Minassian C; Esserman DA; Tate JP; Goetz MB; Bhattacharya D; Fiellin DA; Justice AC; Lo Re V; Rentsch CT
JAMA Netw Open; 2023 Sep; 6(9):e2335715. PubMed ID: 37751206
[TBL] [Abstract][Full Text] [Related]
35. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
36. Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
Cope R; Glowa T; Faulds S; McMahon D; Prasad R
AIDS Patient Care STDS; 2016 Feb; 30(2):51-5. PubMed ID: 26744994
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.
Kaplan DE; Serper M; Kaushik A; Durkin C; Raad A; El-Moustaid F; Smith N; Yehoshua A
J Manag Care Spec Pharm; 2022 Oct; 28(10):1138-1148. PubMed ID: 36125059
[No Abstract] [Full Text] [Related]
38. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost.
Keast SL; Holderread B; Cothran T; Skrepnek GH
J Am Pharm Assoc (2003); 2018; 58(5):485-491. PubMed ID: 30033127
[TBL] [Abstract][Full Text] [Related]
40. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]